Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Public ClinicalTrials.gov record NCT01890265. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To evaluate the safety and tolerability of pamrevlumab in participants with IPF, and the efficacy of pamrevlumab in slowing the loss of forced vital capacity (FVC) and the progression of IPF in these participants.
Study identification
- NCT ID
- NCT01890265
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 160 participants
Conditions and interventions
Conditions
Interventions
- Pamrevlumab Drug
- Placebo Drug
- Sub-Study: Pirfenidone Drug
- Sub-Study: Nintedanib Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 30, 2013 (Actual)
- Primary completion
- Nov 16, 2017 (Actual)
- Completion
- Nov 16, 2017 (Actual)
- Last update posted
- Sep 4, 2020
2013 – 2017
United States locations
- U.S. sites
- 26
- U.S. states
- 22
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Kirklin Clinic | Birmingham | Alabama | 35294 | — |
| David Geffen School of Medicine at UCLA | Los Angeles | California | 90024 | — |
| UC Davis Medical Center | Sacramento | California | 95817 | — |
| National Jewish Health | Denver | Colorado | 80206 | — |
| Yale University | New Haven | Connecticut | 06520 | — |
| Pulmonary Disease Specialist, PA | Kissimmee | Florida | 34741 | — |
| Pensacola Research Consultants, Inc., d.b.a. Avanza Medical Research Center | Pensacola | Florida | 32504 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| University of Kansas Medical Center | Kansas City | Kansas | 66160 | — |
| Via Christi Clinic, P.A. | Wichita | Kansas | 67208 | — |
| University of Louisville | Louisville | Kentucky | 40202 | — |
| University of Maryland | Baltimore | Maryland | 21201 | — |
| Steward St. Elizabeth's Medical Center | Boston | Massachusetts | 02135 | — |
| Henry Ford Medical Center | Detroit | Michigan | 48202 | — |
| St. Luke's Hospital | Chesterfield | Missouri | 63017 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| PulmonIx LLC | Greensboro | North Carolina | 27403 | — |
| University of Cinncinati | Cincinnati | Ohio | 45267 | — |
| Dartmouth-Hitchcock Medical Center | Lebanon | Ohio | 03756 | — |
| Legacy Research Institute | Portland | Oregon | 97210 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15213 | — |
| Vanderbilt University | Nashville | Tennessee | 37232-5735 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
| University of Utah - Lung Health Research | Salt Lake City | Utah | 84108 | — |
| Vermont Lung Center | Colchester | Vermont | 05446 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01890265, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 4, 2020 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01890265 live on ClinicalTrials.gov.